PetVivo is a biomedical device company that develops and sells treatments for joint disease in companion animals, primarily dogs and horses. The company's core product, Spryng, is an injectable device that mimics cartilage and synovial fluid to provide mechanical cushioning and lubrication in joints. PetVivo also offers PrecisePRP, an off-the-shelf platelet-rich plasma product for regenerative therapy. The company markets these products as a combined treatment protocol to licensed veterinary practices. PetVivo reaches customers through wholesale distributors and a direct sales force. The business model generates recurring but infrequent revenue because the effects of its primary injection typically last for one year. The company also offers a subscription-based software platform, PetVivo AI, to assist clinics with practice management and client acquisition. PetVivo is currently pre-profit and relies on external financing to fund its operations. Its strategy involves expanding its domestic sales footprint, entering international markets, and developing a pipeline of biomaterial technologies for orthopedic and cardiovascular applications. The company is also researching piezoelectric biomaterials for tissue and bone regeneration, which may eventually have applications in human medicine.